A new trading day began on Monday, with Celldex Therapeutics Inc (NASDAQ: CLDX) stock price down -5.03% from the previous day of trading, before settling in for the closing price of $22.46. CLDX’s price has ranged from $20.91 to $53.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 53.25%. Meanwhile, its annual earnings per share averaged 15.23%. With a float of $64.66 million, this company’s outstanding shares have now reached $66.34 million.
Let’s determine the extent of company efficiency that accounts for 160 employees. In terms of profitability, gross margin is 76.63%, operating margin of -1745.97%, and the pretax margin is -1544.48%.
Celldex Therapeutics Inc (CLDX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 2.54%, while institutional ownership is 109.80%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SVP AND CFO sold 17,172 for $35.42, making the entire transaction worth $608,315. This insider now owns 28,125 shares in total.
Celldex Therapeutics Inc (CLDX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.99% during the next five years compared to 27.41% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Here are Celldex Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 24.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 141.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.57, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -3.28 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Looking closely at Celldex Therapeutics Inc (NASDAQ: CLDX), its last 5-days average volume was 0.54 million, which is a drop from its year-to-date volume of 0.93 million. As of the previous 9 days, the stock’s Stochastic %D was 43.76%. Additionally, its Average True Range was 1.18.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 3.09%, which indicates a significant decrease from 12.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.55% in the past 14 days, which was lower than the 50.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.40, while its 200-day Moving Average is $31.85. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $22.17. Second resistance stands at $23.01. The third major resistance level sits at $23.45. If the price goes on to break the first support level at $20.89, it is likely to go to the next support level at $20.45. Now, if the price goes above the second support level, the third support stands at $19.61.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
With a market capitalization of 1.42 billion, the company has a total of 66,344K Shares Outstanding. Currently, annual sales are 6,880 K while annual income is -141,430 K. The company’s previous quarter sales were 3,190 K while its latest quarter income was -42,120 K.
